Muhsin KONUK, Ebru ÖZKAN OKTAY, Tuğba KAMAN, Ömer Faruk KARASAKAL, Salih TUNCAY, Öznur Özge ÖZCAN, Tuğçe SOYLAMIŞ, Mesut KARAHAN

An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms

Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory tract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have been developed and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variants of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B 1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurological manifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescent plasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratory tract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccines that have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and its correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs, and action against emerging viral mutant variants is needed.

PDF

___

Almubaid Z, Al-Mubaid H. (2021). Analysis and comparison of genetic variants and mutations of the novel coronavirus SARS-CoV-2. Gene Reports 23: 101064. doi: 10.1016/j. genrep.2021.101064
Antony AR, Haneef Z (2020). Systematic review of EEG findings in 617 patients diagnosed with COVID-19. Seizure. 83: 234-241. doi: 10.1016/j.seizure.2020.10.014
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S et al. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine 384 (5): 403-416. doi: 10.1056/nejmoa2035389
Baig AM, Khaleeq A, Ali U, Syeda H (2020). Evidence of the COVID-19 virus targeting the CNS: tissue distribution, hostvirus interaction, and proposed neurotropic mechanisms. ACS Chemical Neuroscience 11 (7): 995-998. doi: 10.1021/ acschemneuro.0c00122
Beigel JH (2018). Polyclonal and monoclonal antibodies for the treatment of influenza. Current Opinion in Infectious Diseases, 31 (6): 527-534. doi: 10.1097/QCO.0000000000000499
Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P et al. (2021). Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clinical Microbiology and Infection. doi: 10.1016/j. cmi.2021.05.022
Cai Q, Yang M, Liu D, Chen J, Shu D et al. (2020). Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. doi: 10.1016/j.eng.2020.03.007
Callejon-Leblic MA, Moreno-Luna R, Del Cuvillo A, Reyes-Tejero IM, Garcia-Villaran MA et al. (2021). Loss of smell and taste can accurately predict COVID-19 infection: a machinelearning approach. Journal of Clinical Medicine 10 (4): 570. doi: 10.3390/jcm10040570
Charkiewicz R, Nikliński J, Biecek P, Kiśluk J, Pancewicz S et al. (2021). The first SARS-CoV-2 genetic variants of concern (VOC) in Poland: The concept of a comprehensive approach to monitoring and surveillance of emerging variants. Advances in Medical Sciences 66 (2): 237-245. doi: 10.1016/j. advms.2021.03.005
Chen X, Laurent S, Onur OA, Kleineberg NN, Fink GR et al. (2021). A systematic review of neurological symptoms and complications of COVID-19. Journal of Neurology 268 (2): 392-402. doi: 10.1007/s00415-020-10067-3
Cheng MH, Krieger JM, Kaynak B, Arditi M, Bahar I (2021). Impact of South African 501.V2 variant on SARS-CoV-2 spike infectivity and neutralization: A structure-based computational assessment. BioRxiv. doi: 10.1101/2021.01.10.426143
Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP et al. (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccineelicited antibodies. Nature 593: 136-141. doi: 10.1038/s41586- 021-03412-7
Coutinho RM, Marquitti FMD, Ferreira LS, Borges ME, da Silva RLP et al. (2021). Model-based evaluation of transmissibility and reinfection for the P.1 variant of the SARS-CoV-2. MedRxiv. doi: 10.1101/2021.03.03.21252706
Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M et al. (2020). A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrobial Agents and Chemotherapy 64 (9): 1-14. doi: 10.1128/AAC.01061-20
Dastan F, Alireza S, Saffaei A, Marjani M, Moniri A (2020). Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial Farzaneh. International Immunopharmacology Journal 85. doi: 10.1016/j. intimp.2020.106688
Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ et al. (2021). Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372 (6538): eabg3055. doi: 10.1126/science.abg3055
De Stefano P, Nencha U, De Stefano L, Mégevand P, Seeck M et al. (2020). Focal EEG changes indicating critical illness associated cerebral microbleeds in a Covid-19 patient. Clinical Neurophysiology Practice 5: 125-129. doi: 10.1016/j. cnp.2020.05.004
Dejnirattisai W, Zhou D, Supaşa P, Liu C, Mentzer AJ, Ginn HM et al. (2021). Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184 (11): 2939-2954. doi: 10.1016/j.cell.2021.03.055
Deshpande SV, Mali DP (2020). Reverse transcriptase inhibitors: Potential drug delivery combating COVID-19. International Journal of Pharmaceutical Chemistry and Analysis. doi: 10.18231/j.ijpca.2020.026
Dixon L, Varley J, Gontsarova A, Mallon D, Tona F et al. (2020). COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. Neurology(R) Neuroimmunology & Neuroinflammation 7 (5): 1-6. doi: 10.1212/NXI.0000000000000789
Dong M, Zhang J, Ma X, Tan J, Chen L et al. (2020). ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomedicine and Pharmacotherapy 131: 110678. doi: 10.1016/j.biopha.2020.110678
Engelman KD, Engelman AN (2021). D614G and SARS-CoV-2 replication fitness. Signal Transduction and Targeted Therapy 6 (1): 99. doi: 10.1038/s41392-021-00498-3
Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS et al. (2021). Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. 821: 815-821.
Fraiman P, Godeiro Junior, C, Moro E, Cavallieri F, Zedde M (2020). COVID-19 and cerebrovascular diseases: a systematic review and perspectives for stroke management. Frontiers in Neurology 11: 574694. doi: 10.3389/fneur.2020.574694
Francisco R da S, Benites LF, Lamarca AP, de Almeida LGP, Hansen AW et al. (2021). Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 coinfection events by two different lineages in Rio Grande do Sul, Brazil. Virus Research 296. doi: 10.1016/j.virusres.2021.198345
Franke C, Ferse C, Kreye J, Reincke SM, Sanchez-Sendin E et al. (2021). High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain, Behavior, and Immunity 93 (December 2020): 415-419. doi: 10.1016/j.bbi.2020.12.022
Frediansyah A, Tiwari R, Sharun K, Dhama K, Harapan H (2021). Antivirals for COVID-19: A critical review. Clinical Epidemiology and Global Health. doi: 10.1016/j. cegh.2020.07.006
Freeman CW, Masur J, Hassankhani A, Wolf RL, Levine JM et al. (2021). Coronavirus disease (COVID-19)-related disseminated leukoencephalopathy: a retrospective study of findings on brain MRI. American Journal of Roentgenology 216 (4): 1046- 1047. doi: 10.2214/AJR.20.24364
Galanopoulou AS, Ferastraoaru V, Correa DJ, Cherian K, Duberstein S et al. (2020). EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: A small case series preliminary report. Epilepsia Open 5 (2): 314-324. doi: 10.1002/epi4.12399
Gattinger P, Borochova K, Dorofeeva Y, Henning R, Kiss R et al. (2021). Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding. Allergy: European Journal of Allergy and Clinical Immunology 76 (3): 878-883. doi: 10.1111/all.14523
Gómez CE, Perdiguero B, Esteban M (2021). Emerging sars-cov-2 variants and impact in global vaccination programs against sars-cov-2/covid-19. Vaccines 9 (3): 1-13. doi: 10.3390/ vaccines9030243
Goncalves Cabecinhas AR, Roloff T, Stange M, Bertelli C, Huber M et al. (2021). Sars-cov-2 n501y introductions and transmissions in switzerland from beginning of october 2020 to february 2021—implementation of swiss-wide diagnostic screening and whole genome sequencing. Microorganisms 9 (4). doi: 10.3390/microorganisms9040677
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M (2020). The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus. Journal of Biological Chemistry. doi: 10.1074/jbc.AC120.013056
Graci JD, Cameron CE (2006). Mechanisms of action of ribavirin against distinct viruses. Reviews in Medical Virology doi: 10.1002/rmv.483
Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S et al. (2014). Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A double-blind, randomised, placebo-controlled, phase 2b/3 trial. The Lancet Infectious Diseases. doi: 10.1016/S1473-3099(14)70717-0
Hansen J, Baum A, Pascal KE, Russo V, Giordano S et al. (2020). Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369 (6506): 1010- 1014. doi: 10.1126/science.abd0827
He F, Deng Y, Li W (2020). Coronavirus disease 2019: What we know? Journal of Medical Virology 92 (7): 719-725. doi: 10.1002/jmv.25766
Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF et al. (2021). SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184(9): 2384-2393.e12. doi: 10.1016/j. cell.2021.03.036
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T et al. (2020a). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181 (2): 271-280.e8. doi: 10.1016/j. cell.2020.02.052
Hoffmann M, Kleine-Weber H, Pöhlmann S (2020b). A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Molecular Cell 78 (4): 779-784. e5. doi: 10.1016/j.molcel.2020.04.022
Hurt AC, Wheatley AK (2021). Neutralizing antibody therapeutics for COVID-19. Viruses 13(4) 1-15. doi: 10.3390/v13040628
Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Krammer F et al. (2021). The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. MedRxiv.
Jiang Y, Chen D, Cai D, Yi Y, Jiang S (2021). Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: A network meta-analysis. Journal of Medical Virology. doi: 10.1002/jmv.26443
Ju B, Zhang Q, Ge J, Wang R, Sun J et al. (2020). Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584 (7819): 115-119. doi: 10.1038/s41586-020-2380-z
Kelleni MT (2020). Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacological Research. doi: 10.1016/j.phrs.2020.104874
Khan S, Siddique R, Shereen MA, Ali A, Liu J et al. (2020). The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options. Journal of Clinical Microbiology 23; 58 (5): e00187-20. doi: 10.1128/JCM.00187-20
Kim JH, Marks F, Clemens JD (2021). Looking beyond COVID-19 vaccine phase 3 trials. Nature Medicine 27 (2): 205-211 doi: 10.1038/s41591-021-01230-y
Kocayiğit H, Özmen Süner K, Tomak Y, Demir G, Yaylacı S et al. (2021). Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. Journal of Clinical Pharmacy and Therapeutics 46: 454-459. doi: 10.1111/jcpt.13305
Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J et al. (2020). Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell 182 (4): 812- 827.e19. doi: 10.1016/j.cell.2020.06.043
Kubota T, Gajera PK, Kuroda N (2021). Meta-analysis of EEG findings in patients with COVID-19. Epilepsy Behavior 115: 107682. doi: 10.1016/j.yebeh.2020.107682.
Lambrecq V, Hanin A, Munoz-Musat E, Chougar L, Gassama S et al. (2021). Association of clinical, biological, and brain magnetic resonance imaging findings with electroencephalographic findings for patients with COVID-19. JAMA Network Open 4 (3): 1-14. doi: 10.1001/jamanetworkopen.2021.1489
Lamprou DA (2020). Emerging technologies for diagnostics and drug delivery in the fight against COVID-19 and other pandemics. Expert Review of Medical Devices doi: 10.1080/17434440.2020.1792287
Lewis A, Frontera J, Placantonakis DG, Lighter J, Galetta S et al. (2021). Cerebrospinal fluid in COVID-19: A systematic review of the literature. Journal of the Neurological Sciences 15 (421): 117316. doi: 10.1016/j.jns.2021.117316
Lin L, Al-Faraj A, Ayub N, Bravo P, Das S et al. (2021). Electroencephalographic abnormalities are common in COVID-19 and are associated with outcomes. Annals of Neurology 89 (5): 872-883. doi: 10.1002/ana.26060
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV et al. (2021). Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet 397 (10275): 671-681. doi: 10.1016/ S0140-6736(21)00234-8
Luan B, Wang H, Huynh T (2021). Enhanced binding of the N501Ymutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations. FEBS Letters 595 (10): 1454-1461. doi: 10.1002/1873-3468.14076
Mahammedi A, Saba L, Vagal A, Leali M, Rossi A et al. (2020). Imaging of neurologic disease in hospitalized patients with COVID-19: An italian multicenter retrospective observational study. Radiology 297 (2): E270-E273. doi: 10.1148/ RADIOL.2020201933
Meppiel E, Peiffer-Smadja N, Maury A, Bekri I, Delorme C et al. (2021). Neurologic manifestations associated with COVID-19: a multicentre registry. Clinical Microbiology and Infection 27 (3): 458-466. doi:10.1016/j.cmi.2020.11.005
Meunier N, Briand L, Jacquin-Piques A, Brondel L, Pénicaud L (2021). COVID 19-induced smell and taste impairments: putative impact on physiology. Frontiers in Physiology 11 (January): 1-12. doi: 10.3389/fphys.2020.625110
Mutiawati E, Fahriani M, Mamada SS, Fajar JK, Frediansyah A et al. (2021). Anosmia and dysgeusia in SARS-CoV-2 infection: Incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms- a systematic review and meta-analysis. F1000Research 10: 1-28. doi: 10.12688/ f1000research.28393.1
Oral HB, Akdiş CA, Özakin C (2002). Back to the future: Antibodybased strategies for the treatment of infectious diseases. Applied Biochemistry and Biotechnology- Part B Molecular Biotechnology 21 (3): 225-239. doi: 10.1385/MB:21:3:225
Owji H, Negahdaripour M, Hajighahramani N (2020). Immunotherapeutic approaches to curtail COVID-19. International Immunopharmacology 88 (July): 106924. doi: 10.1016/j.intimp.2020.106924
Ozono S, Zhang Y, Ode H, Sano K, Tan TS et al. (2021). SARSCoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nature Communications 12 (1). doi: 10.1038/s41467-021-21118-2
Paliwal VK, Garg RK, Gupta A, Tejan N (2020). Neuromuscular presentations in patients with COVID-19. Neurological Sciences 41 (11): 3039-3056. doi: 10.1007/s10072-020-04708-8
Pastuch-Gawołek G, Gillner D, Król E, Walczak K, Wandzik I (2019). Selected nucleos(t)ide-based prescribed drugs and their multi-target activity. European Journal of Pharmacology. doi: 10.1016/j.ejphar.2019.172747
Pearson CA, Russell TW, Davies NG, Kucharski AJ, CMMID COVID-19 working group et al. (2021). Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2. Preprint 50: 1-4.
Pennisi M, Lanza G, Falzone L, Fisicaro F, Ferri R et al. (2020). Sars-cov-2 and the nervous system: From clinical features to molecular mechanisms. International Journal of Molecular Sciences 21 (15): 1-21. doi: 10.3390/ijms21155475
Plante JA, Liu Y, Liu J, Xia H, Johnson BA et al. (2021). Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592 (7852): 116-121. doi: 10.1038/s41586-020-2895-3
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383 (27): 2603-2615. doi: 10.1056/nejmoa2034577
Public Health England (2020). Investigation of novel SARSCOV-2 variant Variant of Concern 202012 / 01 Detection of an epidemiological cluster associated with a new variant of concern Nomenclature of variants in the UK Current epidemiological findings. December, 1-11.
Public Health England (2021). SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 10. 8: 1-50.
Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y et al. (2020). Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. In Allergy: European Journal of Allergy and Clinical Immunology 75 (11). doi: 10.1111/all.14429
Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y et al. (2020). Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathologica 140 (1): 1-6. doi: 10.1007/ s00401-020-02166-2
Roche JA, Roche R (2020). A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. FASEB Journal 34 (6): 7265-7269. doi: 10.1096/fj.202000967
Rossignol JF (2014). Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Research 110 94-103. doi: 10.1016/j. antiviral.2014.07.014
Saha P, Banerjee AK, Tripathi PP, Srivastava AK, Ray U (2020). A virus that has gone viral: Amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity. Bioscience Reports 40 (5): 1-8. doi: 10.1042/BSR20201312
Salcan İ, Karakeçili F, Salcan S, Ünver E, Akyüz S et al. (2021). Is taste and smell impairment irreversible in COVID-19 patients? European Archives of Oto-Rhino-Laryngology 278 (2): 411- 415. doi: 10.1007/s00405-020-06560-0
Sallenave JM, Guillot L (2020). Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in Covid-19: key therapeutic targets? Frontiers in Immunology 11 (May): 1-9. doi: 10.3389/fimmu.2020.01229
Sanjuán R, Domingo-Calap P (2016). Mechanisms of viral mutation. Cellular and Molecular Life Sciences 73 (23): 4433-4448. doi: 10.1007/s00018-016-2299-6
Shang J, Wan Y, Luo C, Ye G, Geng Q et al. (2020). Cell entry mechanisms of SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America 117 (21). doi: 10.1073/pnas.2003138117
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE et al. (2017). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine 9 (396): eaal3653. doi: 10.1126/scitranslmed.aal3653
Taher T, Sheikh AB, Anwar F, Khosa F (2021). SARS-CoV-2: its potential neurological manifestations and plausible mechanism: a review article. Acta Neurologica Belgica 121 (2): 331-339. doi: 10.1007/s13760-020-01577-y
Taquet M, Luciano S, Geddes JR, Harrison PJ (2021). Differential follow-up patterns in COVID-19 and comparison cohorts – Authors’ reply. The Lancet Psychiatry, 8 (5): 360-361. doi: 10.1016/S2215-0366(21)00076-6
Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V et al. (2020). Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARSCoV-2) lineage with multiple spike mutations in South Africa. MedRxiv, 2. doi: 10.1101/2020.12.21.20248640
Tian X, Li C, Huang A, Xia S, Lu S (2020). Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirusspecific human monoclonal antibody. BioRxiv, 9. doi: 10.1101/2020.01.28.923011
Twomey JD, Luo S, Dean AQ, Bozza WP, Nalli A et al. (2020). COVID-19 update: The race to therapeutic development. Drug Resistance Updates, 53 (September): 100733. doi: 10.1016/j. drup.2020.100733
Van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW M, de Mast Q, et al. (2020). Kallikrein-kinin blockade in patients with covid-19 to prevent acute respiratory distress syndrome. ELife 9: 1-9. doi: 10.7554/ELIFE.57555
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 397 (10269): 99-111. doi: 10.1016/S0140- 6736(20)32661-1
Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I (2021). Shortterm safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. The Lancet Oncology 22 (5): 581-583. doi: 10.1016/ S1470-2045(21)00155-8
Walls A, Park Y-J, Tortorici MA, Wall A, McGuire A et al. (2020). Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. doi: 10.1101/2020.02.19.956581
Wang M, Cao R, Zhang L, Yang X, Liu J et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. doi: 10.1038/ s41422-020-0282-0
Wang P, Nair MS, Liu L, Iketani S, Luo Y et al. (2021). Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593 (7857): 130-135. doi: 10.1038/s41586-021-03398-2
Wildwing T, Holt N (2021). The neurological symptoms of COVID-19: a systematic overview of systematic reviews, comparison with other neurological conditions and implications for healthcare services. Therapeutic Advances in Chronic Disease 12. doi: 10.1177/2040622320976979
World Health Organization (2021a). COVID-19 Weekly Epidemiological Update 22: Special edition: Proposed working definitions of SARS-CoV-2 Variants of Interest and Variants of Concern. 25 February 2021.
World Health Organization (2021b). CO COVID-19 Weekly Epidemiological Update Edition 41, published 25 May 2021. World Health Organization (2021c). COVID-19 Weekly Epidemiological Update Data as received by WHO from national authorities, as of 9 May 2021, 10 am CET
Wu Y, Wang F, Shen C, Peng W, Li D et al. (2020). A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. MedRxiv 1278 (June): 1274- 1278. doi: 10.1101/2020.05.01.20077743
Xie X, Liu Y, Liu J, Zhang X, Zou J et al. (2021). Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nature Medicine 27 (4): 620-621. doi: 10.1038/s41591-021-01270-4
Yassin A, Nawaiseh M, Shaban A, Alsherbini K, El-Salem K et al. (2021). Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. BMC Neurology 21 (1): 1-17. doi: 10.1186/ s12883-021-02161-4
Yin W, Luan X, Li Z, Xie Y, Zhou Z et al. (2020). Structural basis for repurpose and design of nucleoside drugs for treating COVID-19. BioRxiv
Yuan M, Wu NC, Zhu X, Lee CCD, So RTY et al. (2020). A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. BioRxiv 633 (May): 630-633. doi: 10.1101/2020.03.13.991570
Yurdakök Dikmen B, Pat Y, Dilekoz E, Summak GY, Kul O et al. (2020). Pharmacotherapy of COVID-19. Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni (in Turkish with an abstract in English). doi: 10.38137/vetfarmatoksbulten.769889
Zhao S, Lou J, Cao L, Zheng H, Chong MKC et al. (2021). Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the UK: an early datadriven analysis. Journal of Travel Medicine 28 (2): 1-3. doi: 10.1093/jtm/taab011
Zheng M, Song L (2020). Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cellular and Molecular Immunology 17 (5): 536- 538. doi: 10.1038/s41423-020-0385-z
Zhou B, Thao TTN, Hoffmann D, Taddeo A, Ebert N et al. (2021). SARS-CoV-2 spike D614G change enhances replication and transmission. Nature 592 (7852): 122-127. doi: 10.1038/ s41586-021-03361-1
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE (2020). Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review. JAMA Neurology 77 (8): 1018-1027. doi: 10.1001/ jamaneurol.2020.2065